Pfizer Buys Into Promise Of Imcyse Imotopes
Rheumatoid Arthritis Alliance Inked
Executive Summary
The US giant is taking a stake in Imcyse and taking over a program to develop RA drugs in a deal that validates the Belgian group's imotope technology.
You may also be interested in...
Finance Watch: $2.2bn In New Funding Sources In February, So Far
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.